GGrantIndex
← Leaderboards

James A Stewart

University Of Wisconsin Madison

Google Scholar ↗PubMed ↗ORCID ↗
$6,121,809
Attributed
$6,121,809
Total exposure
10
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $702.8K · FY2005–11
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11

Funding mix

By agency

NIH$6,121,809 · 10

By mechanism

U10$4,771,184 · 1
P30$860,851 · 3
M01$489,774 · 6

Top collaborators

No co-investigators on record.

Most similar at University Of Wisconsin Madison

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectNeoplasm /Cancer ChemotherapyHuman Therapy EvaluationClinical TrialsNeoplasm /Cancer Radiation TherapyCombination Cancer TherapyAntineoplasticsMelanomaNeoplasm /Cancer ImmunotherapyDrug Screening /EvaluationDatabasesCombination ChemotherapyMedicineLymphomaMemberHealth BehaviorCarcinomaEnsureBone Marrow TransplantationBrain NeoplasmsGliomaFemaleGene Therapy

Grant awards (34)

Data and Safety Monitoring$125,410
P30 · FY2011 · CA · contact PI
Data and Safety Monitoring$114,805
P30 · FY2010 · CA · contact PI
Data and Safety Monitoring$108,976
P30 · FY2009 · CA · contact PI
Data and Safety Monitoring$107,738
P30 · FY2008 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$588,460
U10 · FY2007 · CA · contact PI
Data and Safety Monitoring$114,366
P30 · FY2007 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$594,662
U10 · FY2006 · CA · contact PI
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$604,372
U10 · FY2005 · CA
HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 &IFN IN MELANOMA$17,977
M01 · FY2005 · RR
ZOSUQUIDAR TRIHYDROCHLORIDE IN NEWLY DIAGNOSED AML$2,997
M01 · FY2005 · RR
VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA$1,873
M01 · FY2005 · RR
PHASE II TRIAL OF TWO DOSE LEVELS OF CCI-779 IN EXTENSIVE-STAGE SCLC$374
M01 · FY2005 · RR
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES$604,169
U10 · FY2004 · CA
Zosuquidar Trihydrochloride in Newly Diagnosed AML$13,289
M01 · FY2004 · RR
Phase II Trial of Two Dose Levels of CCI-779 in Extensive-Stage SCLC$577
M01 · FY2004 · RR
High-Dose IFN-alpha-2b vs Cisplatin, Vinblastine, DTIC + IL-2 &IFN in Melanoma$577
M01 · FY2004 · RR
EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES$623,064
U10 · FY2003 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES$604,916
U10 · FY2002 · CA
PHASE II TRIAL OF IL 12 IN ADVANCED RECURRENT OR INOPERABLE CERVICAL$106,600
M01 · FY2002 · RR
PHASE I IDURD AND ACCELERATED HYPERFRACTIONATED XRT FOR HIGH GRADE GLIOMAS$106,600
M01 · FY2002 · RR
CORE--PROTOCOL REVIEW AND MONITORING$0
P30 · FY2002 · CA
CORE--CLINICAL TRIALS RESEARCH OFFICE$0
P30 · FY2002 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES$587,298
U10 · FY2001 · CA
PHASE I IDURD AND ACCELERATED HYPERFRACTIONATED XRT FOR HIGH GRADE GLIOMAS$106,600
M01 · FY2001 · RR
PHASE II TRIAL OF IL 12 IN ADVANCED RECURRENT OR INOPERABLE CERVICAL$106,600
M01 · FY2001 · RR
PHASE II TRIAL OF IL 12 IN ADVANCED RECURRENT OR INOPERABLE CERVICAL$12,855
M01 · FY2001 · RR
PHASE I IDURD AND ACCELERATED HYPERFRACTIONATED XRT FOR HIGH GRADE GLIOMAS$12,855
M01 · FY2001 · RR
CORE--PROTOCOL REVIEW AND MONITORING$0
P30 · FY2001 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIES$564,243
U10 · FY2000 · CA
CORE--CLINICAL TRIALS RESEARCH OFFICE$289,556
P30 · FY2000 · CA
PHASE I IDURD AND ACCELERATED HYPERFRACTIONATED XRT FOR HIGH GRADE GLIOMAS$0
M01 · FY2000 · RR
PHASE II TRIAL OF IL 12 IN ADVANCED RECURRENT OR INOPERABLE CERVICAL$0
M01 · FY2000 · RR
PHASE II TRIAL OF IL 12 IN ADVANCED RECURRENT OR INOPERABLE CERVICAL$0
M01 · FY2000 · RR
PHASE I IDURD AND ACCELERATED HYPERFRACTIONATED XRT FOR HIGH GRADE GLIOMAS$0
M01 · FY2000 · RR